Back to Newsroom

Global Genomics Group (G3) Completes Patient Enrollment Of Discovery Cohort In GLOBAL Study Ahead Of Schedule

RICHMOND, Va., Feb. 13, 2014 – Global Genomics Group (G3) today announced that it has completed enrollment of the 5,000-patient discovery cohort of its GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) clinical study. Pilot data for the first cohort of patients are expected later this year.